Q&A with Amie Gehris, Dow Water and Process Solutions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Amie Gehris, Dow Water and Process Solutions
Amie Gehris of Dow Water and Process Solutions discusses formulating abuse-deterrent drugs.

Pharmaceutical Technology
Volume 37, Issue 10, pp. 96

Amie Gehris
Technical Service Manager, Healthcare and Specialty Nutrition, Dow Water and Process Solutions

Amie Gehris

PharmTech: Abuse-deterrent drugs have come into prominence with the recent issuance of FDA draft guidance. What is meant by an abuse-deterrent drug and what role does the formulation play?

Gehris: Whether intentional or unintentional, the abuse of certain drugs can be life threatening. One of the best known types of deliberate drug abuse is that of opiates, such as oxycodone, which has been linked to numerous deaths. However, unintentional abuse--chewing sustained-release formulation drugs, for example--is also potentially lethal. Loading an API onto a resin to create a resinate can slow the release of a drug sufficiently to reduce or eliminate the potential for lethal concentrations of active drugs in the body. The API remains bound within the resin, so the rate of absorption is reduced. This technology is used to reduce the high risk associated with intentional abuse, thus reducing the likelihood of overdose and making illicit extraction more difficult and less efficient.

PharmTech: What are specialized considerations in formulating an abuse-deterrent drug, including excipient functionality?

Gehris: Based on the new FDA standards for controlled substances, new formulations must have abuse-deterrent features, including a crush-proof component. Historically, the controlled release of the drug was the matrix tablet ingredients themselves. When the controlled-release mechanism of the tablet was compromised by crushing, the drug was immediately available in a large dose. The current drug-delivery system has a crush-proof component that prohibits dose dumping from the controlled-release formulation. This is the standard by which FDA is basing its criteria for accepting generic formulations into the US market.

Functional excipients, such as ion-exchange resins, have a direct impact on the availability of the API. Ion-exchange resins modify the release of drugs and reduce the immediate availability of the API, whether or not the integrity of the tablet thas been compromised. There are commercial examples of ion-exchange resins being used successfully in suspension formulations to modify the release of APIs over a period of time. A coating strategy is typically employed in these instances. Also, ion-exchange technology reduces the dose-dumping effects when alcohol is present, making them useful for abuse-deterrent formulations.

PharmTech: What testing is used in formulating an abuse-deterrent drug?

Gehris: Slight modifications of standard testing may be necessary when employing an ion-exchange strategy to a formulation. Typical dissolution testing, either static or dynamic, can be used. Dissolution media may have to be altered slightly to achieve acceptance criteria for quality-control release protocols by increasing the ion background. Also, assay testing includes removing the drug from the resin before testing with typical analytical methods by displacing it with salt, acid, or a combination of those materials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here